BioWorld

Feb. 23, 2004

La Jolla Raises $27M Following FDA Acceptance Of Riquent NDA

Graffinity Raises EUR15M In Third Round For Discovery Programs

Other News To Note

Appointments And Advancements

U.S. Patent Disclosures

Facing Rising Costs For Clinical Trials, Rigel Offering Raises $57M

Raking in net proceeds of $57 million, Rigel Pharmaceuticals Inc. more than doubled its cash reserves after pricing a common stock offering. (BioWorld Today) Read More

FDA Losing Chief: Bush Taps McClellan As Leader Of CMS

Today's news in brief

BioWorld

BioWorld briefs for Dec. 31, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 31, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...

Big pharma taps fast Asia innovation in search of next Keytruda

BioWorld

Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...